Last updated: February 13, 2026
Market Analysis and Price Projections for NDC 44567-0701
Overview
The National Drug Code (NDC) 44567-0701 refers to Darzalex (daratumumab), a monoclonal antibody approved for multiple myeloma treatment. Since its FDA approval in 2015, Darzalex has seen rapid adoption in oncology, driven by its efficacy and expanding indications. The drug is marketed by Janssen Pharmaceuticals.
Market Size and Growth Trajectory
Current Market Landscape
- Global Multiple Myeloma Market (2022): Estimated at USD 19.8 billion [1].
- Darzalex's Share: Approximate USD 6.5 billion in 2022 revenue, representing nearly 33% of the global multiple myeloma treatment market [2].
Growth Drivers
- Increased diagnosis rates owing to improved detection methods.
- Expanded indications: multiple myeloma patients are eligible for Darzalex in earlier lines of therapy.
- Combination regimens: Usage alongside other therapies (e.g., pomalidomide, bortezomib) enhances effectiveness.
Competitive Landscape
Darzalex faces competition from other monoclonal antibodies (e.g., Celgene's Revlimid, Takeda's Ninlaro) and emerging therapies, including CAR T-cell treatments. However, it maintains a dominant market position due to proven survival benefit.
Pricing and Reimbursement Environment
List Price and Actual Patient Cost
- FDA-Approved Dose: 16 mg/kg IV infusion.
- Average Wholesale Price (AWP): Approx USD 4,500 per 100 mg vial; typical treatment involves 4-8 vials per cycle.
- Average per treatment cycle: Approximately USD 36,000.
Reimbursement Factors
- Reimbursement varies across countries and insurers:
- US: Medicare and private insurers typically cover the cost with prior authorization.
- EU and Asia: Pricing is negotiated individually, with substantial discounts often applied.
Price Projections (2023-2028)
| Year |
Estimated Average Price per Treatment Cycle |
Basis/Notes |
| 2023 |
USD 36,000 |
Stable pricing following manufacturer list prices; shift expected due to biosimilar entry. |
| 2024 |
USD 34,000 |
Slight decrease anticipated with biosimilar developments and market competition. |
| 2025 |
USD 32,000 |
Pressure from biosimilar products expected to accelerate price reductions. |
| 2026 |
USD 30,000 |
Biosimilar entry in major markets, pricing negotiations intensify. |
| 2027 |
USD 28,000 |
Market consolidation with biosimilar adoption increasing. |
| 2028 |
USD 27,000 |
Full biosimilar market penetration expected; cost focus drives further declines. |
Note: These projections assume continued adoption and biosimilar emergence, not accounting for potential regulatory or patent challenges.
Biosimilar Impact
- Biosimilar Launches: Expected from 2024 onwards in major markets.
- Price Reductions: Biosimilars are projected to reduce prices by 20-40%, depending on market dynamics, patent litigation, and healthcare policies.
Regulatory and Policy Influence
- Patent Expirations: Trials for biosimilar approval in the US and Europe are underway; exclusivity periods influence timing.
- Healthcare Policies: Cost containment measures may accelerate biosimilar uptake and price reductions.
Key Takeaways
- The market for Darzalex remains robust, with steady growth driven by expanding indications.
- List prices will likely decline progressively from 2024 onward due to biosimilar competition.
- Market share might shift as biosimilars penetrate, pressing down on overall pricing.
- Reimbursement policies and healthcare reforms will significantly influence net prices.
- The entry of biosimilars is expected to reduce treatment costs by approximately 25-35% by 2028.
5 FAQs
1. How does Darzalex's pricing compare to other monoclonal antibodies?
Darzalex’s list price per cycle (~USD 36,000) aligns closely with other monoclonal antibodies used in oncology, such as Rituxan and Herceptin, although actual costs vary by indication, dose, and market.
2. When are biosimilars expected in major markets?
Biosimilars for daratumumab are in late-stage development, with approvals anticipated beginning in 2024-2025 in the US, Europe, and Japan.
3. Will biosimilars significantly impact the market share of Darzalex?
Yes. Biosimilar entry typically results in rapid market share erosion, especially when coupled with cost savings and reimbursement incentives.
4. How do pricing policies differ internationally?
Pricing negotiations in Europe and Asia are more centralized and discount-focused, whereas US prices are often list prices with varied reimbursement levels.
5. What are the main factors influencing the price decline of Darzalex?
Patent expiration, biosimilar competition, healthcare policies, and physician prescribing trends all drive prices downward.
References
[1] MarketWatch. Global Multiple Myeloma Market Size and Growth Analysis (2022).
[2] Janssen Pharmaceuticals. Annual Financial Report (2022).
[3] IQVIA. Pharmaceutical Market Data (2022).
[4] FDA. Darzalex (daratumumab) Approval Summary (2015).
[5] Health Economics. Impact of Biosimilar Entry on Monoclonal Antibody Pricing (2022).
